BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Gilteritinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Gilteritinib\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06001788-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Gilteritinib: Phase 1 readout est. (NCT06001788)
DESCRIPTION:Gilteritinib\, phase 1\, Acute Myeloid Leukemia.\nStudy: Safety
  and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Ref
 ractory Acute Myeloid Leukemia\nEstimated primary completion: December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/gilteritinib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06001788
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05955261-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Gilteritinib: Phase 2 readout est. (NCT05955261)
DESCRIPTION:Gilteritinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Stud
 y of Venetoclax in Combination With Conventional Chemotherapy in Pediatric
  Patients With Acute Myeloid Leukemia\nEstimated primary completion: Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gilteritini
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 955261
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05010772-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Gilteritinib: Phase 1 readout est. (NCT05010772)
DESCRIPTION:Gilteritinib\, phase 1\, Acute Myeloid Leukemia.\nStudy: Decita
 bine Alone or in Combination With Venetoclax\, Gilteritinib\, Enasidenib\,
  or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid L
 eukemia in Remission\nEstimated primary completion: 31 December 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/gilteritinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05010772
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06222580-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Gilteritinib: Phase 1 readout est. (NCT06222580)
DESCRIPTION:Gilteritinib\, phase 1\, Acute Myeloid Leukemia.\nStudy: SNDX-5
 613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Muta
 ted Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutati
 on\nEstimated primary completion: 31 January 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/gilteritinib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06222580
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05024552-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20270215
DTEND;VALUE=DATE:20270216
SUMMARY:Gilteritinib: Phase 1 readout est. (NCT05024552)
DESCRIPTION:Gilteritinib\, phase 1\, Acute Myeloid Leukemia.\nStudy: Vyxeos
  Plus Gilteritinib in Relapsed or Refractory\, FLT3-Mutated AML\nEstimated
  primary completion: 15 February 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/gilteritinib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05024552
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05756777-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20270421
DTEND;VALUE=DATE:20270422
SUMMARY:Gilteritinib: Phase 1 readout est. (NCT05756777)
DESCRIPTION:Gilteritinib\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Stud
 y of Gilteritinib in Combination With Ivosidenib or Enasidenib in People W
 ith Acute Myeloid Leukemia (AML)\nEstimated primary completion: 21 April 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/gilteritinib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0575677
 7
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06225427-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Gilteritinib: Phase 1 readout est. (NCT06225427)
DESCRIPTION:Gilteritinib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Gi
 lteritinib for the Treatment of ALK NSCLC\nEstimated primary completion: M
 ay 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/gilteritinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT062
 25427
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07548710-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Gilteritinib: Phase 2 readout est. (NCT07548710)
DESCRIPTION:Gilteritinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Study 
 of SA+X in the Treatment of Newly Diagnosed AML\nEstimated primary complet
 ion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gil
 teritinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07548710
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07032727-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Gilteritinib: Phase 2 readout est. (NCT07032727)
DESCRIPTION:Gilteritinib\, phase 2.\nStudy: Olutasidenib Combined With Co-t
 argeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancie
 s Harboring Activated Signaling Pathway Mutations\nEstimated primary compl
 etion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/g
 ilteritinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07032727
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04988555-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Gilteritinib: Phase 1/2 readout est. (NCT04988555)
DESCRIPTION:Gilteritinib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Ph
 ase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Hor
 izen-1)\nEstimated primary completion: 30 June 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/gilteritinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT04988555
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06235801-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Gilteritinib: Phase 1/2 readout est. (NCT06235801)
DESCRIPTION:Gilteritinib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Ph
 ase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed 
 or Refractory FLT3-Mutated Acute Myeloid Leukemia\nEstimated primary compl
 etion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/gilteritinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06235801
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05010122-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Gilteritinib: Phase 1/2 readout est. (NCT05010122)
DESCRIPTION:Gilteritinib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: ASTX
 727\, Venetoclax\, and Gilteritinib for the Treatment of Newly Diagnosed\,
  Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk M
 yelodysplastic Syndrome\nEstimated primary completion: 30 January 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/gilteritinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05010122
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06265545-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Gilteritinib: Phase na readout est. (NCT06265545)
DESCRIPTION:Gilteritinib\, phase na\, Acute Myeloid Leukemia.\nStudy: Multi
 center\, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloi
 d Leukemia\nEstimated primary completion: 30 January 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/gilteritinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06265545
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07131059-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20280510
DTEND;VALUE=DATE:20280511
SUMMARY:Gilteritinib: Phase na readout est. (NCT07131059)
DESCRIPTION:Gilteritinib\, phase na\, Acute Myeloid Leukemia.\nStudy: MRD-p
 ositive AML Clinical Study\nEstimated primary completion: 10 May 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/gilteritinib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07131059
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07463651-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Gilteritinib: Phase 3 readout est. (NCT07463651)
DESCRIPTION:Gilteritinib\, phase 3\, Acute Myeloid Leukemia.\nStudy: MRD-gu
 ided Maintenance Post-HCT: Gilteritini vs Sorafenib\nEstimated primary com
 pletion: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /gilteritinib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07463651
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05199051-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20280710
DTEND;VALUE=DATE:20280711
SUMMARY:Gilteritinib: Phase 2 readout est. (NCT05199051)
DESCRIPTION:Gilteritinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Phas
 e 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults
  With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML\nEstimated pri
 mary completion: 10 July 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/gilteritinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05199051
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05520567-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Gilteritinib: Phase 1/2 readout est. (NCT05520567)
DESCRIPTION:Gilteritinib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A St
 udy of Gilteritinib\, Venetoclax and Azacitidine as a Combined Treatment f
 or People Newly Diagnosed With Acute Myeloid Leukemia\nEstimated primary c
 ompletion: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/gilteritinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05520567
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06667973-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Gilteritinib: Phase 2 readout est. (NCT06667973)
DESCRIPTION:Gilteritinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Effica
 cy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-p
 ositive Acute Myeloid Leukemia\nEstimated primary completion: August 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/gilteritinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06667973
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06992934-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Gilteritinib: Phase na readout est. (NCT06992934)
DESCRIPTION:Gilteritinib\, phase na.\nStudy: Immunological Impact of a Post
  Cell Therapy Treatment With FLT3 Inhibitors\nEstimated primary completion
 : August 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gilter
 itinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06992934
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04140487-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Gilteritinib: Phase 1/2 readout est. (NCT04140487)
DESCRIPTION:Gilteritinib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Azac
 itidine\, Venetoclax\, and Gilteritinib in Treating Patients With Recurren
 t/Refractory FLT3-Mutated Acute Myeloid Leukemia\, Chronic Myelomonocytic 
 Leukemia\, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neopla
 sm\nEstimated primary completion: 1 September 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/gilteritinib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT04140487
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07425808-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Gilteritinib: Phase 2/3 readout est. (NCT07425808)
DESCRIPTION:Gilteritinib\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: FLT3
 -ITD Targeted Therapy in Fit AML Patients\nEstimated primary completion: 1
  October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gilter
 itinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07425808
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06221683-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Gilteritinib: Phase 2 readout est. (NCT06221683)
DESCRIPTION:Gilteritinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Clinic
 al Study of Induction Therapy Options Based on Molecular Subtyping and MRD
  in Children and Adolescents With AML\nEstimated primary completion: Decem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gilteritini
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 221683
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07259707-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Gilteritinib: Phase 2 readout est. (NCT07259707)
DESCRIPTION:Gilteritinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Gilter
 itinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed F
 LT3-ITD+ AML\nEstimated primary completion: 31 December 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/gilteritinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07259707
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407140-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Gilteritinib: Phase 3 readout est. (NCT07407140)
DESCRIPTION:Gilteritinib\, phase 3\, Acute Myeloid Leukemia.\nStudy: VAG Ve
 rsus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3
 -Mutated AML\nEstimated primary completion: 1 February 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/gilteritinib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07407140
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06696183-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Gilteritinib: Phase 2 readout est. (NCT06696183)
DESCRIPTION:Gilteritinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Gilter
 itinib in Combination With Venetoclax and Azacitidine for AML Patients Wit
 h FLT3 Mutations Ineligible for Intensive Treatment\nEstimated primary com
 pletion: April 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 gilteritinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06696183
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05564390-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20290515
DTEND;VALUE=DATE:20290516
SUMMARY:Gilteritinib: Phase 2 readout est. (NCT05564390)
DESCRIPTION:Gilteritinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: MYELOM
 ATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatmen
 t Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screen
 ing Trial)\nEstimated primary completion: 15 May 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/gilteritinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05564390
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06317649-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20290515
DTEND;VALUE=DATE:20290516
SUMMARY:Gilteritinib: Phase 2 readout est. (NCT06317649)
DESCRIPTION:Gilteritinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Veneto
 clax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute M
 yeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)\nEstimated primary co
 mpletion: 15 May 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/gilteritinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06317649
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04293562-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Gilteritinib: Phase 3 readout est. (NCT04293562)
DESCRIPTION:Gilteritinib\, phase 3\, Acute Myeloid Leukemia.\nStudy: A Stud
 y to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilterit
 inib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations\
 nEstimated primary completion: 30 June 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/gilteritinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT04293562
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07755202-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Gilteritinib: Phase 2 readout est. (NCT07755202)
DESCRIPTION:Gilteritinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Gilter
 itinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapse
 d/Refractory Leukemia\nEstimated primary completion: 1 October 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/gilteritinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07755202
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07140016-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Gilteritinib: Phase 1 readout est. (NCT07140016)
DESCRIPTION:Gilteritinib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell 
 Lung Cancer (NSCLC)\nEstimated primary completion: 31 December 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/gilteritinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07140016
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07949370-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Gilteritinib: Phase 2 readout est. (NCT07949370)
DESCRIPTION:Gilteritinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Phas
 e 2 Study of Dynamic BH3 Profiling (DBP) Guided Combination Therapy in Sub
 jects With R/R AML\nEstimated primary completion: 31 December 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/gilteritinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07949370
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02115295-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Gilteritinib: Phase 2 readout est. (NCT02115295)
DESCRIPTION:Gilteritinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Cladri
 bine\, Idarubicin\, Cytarabine\, and Venetoclax in Treating Patients With 
 Acute Myeloid Leukemia\, High-Risk Myelodysplastic Syndrome\, or Blastic P
 hase Chronic Myeloid Leukemia\nEstimated primary completion: 31 May 2030. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/gilteritinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT02115295
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03013998-2038@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Gilteritinib: Phase 2/3 readout est. (NCT03013998)
DESCRIPTION:Gilteritinib\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: Stud
 y of Biomarker-Based Treatment of Acute Myeloid Leukemia\nEstimated primar
 y completion: December 2032. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/gilteritinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT03013998
URL:https://assetmemo.bio/drug/gilteritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
